Exact Sciences Corp (EXAS)
45.64
+0.85
(+1.90%)
USD |
NASDAQ |
Apr 30, 16:00
46.00
+0.36
(+0.79%)
Pre-Market: 08:35
Key Stats
Price and Performance | |
---|---|
Market Cap | 8.478B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -23.10% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 3.047 |
Price to Book Value | 3.529 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 1.070 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 80.42% |
Profile
Edit
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
URL | https://www.exactsciences.com |
Investor Relations URL | https://investor.exactsciences.com/investor-relations/default.aspx |
HQ State/Province | Wisconsin |
Sector | Health Care |
Industry | Biotechnology |
Next Earnings Release | May. 01, 2025 |
Last Earnings Release | May. 01, 2025 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
URL | https://www.exactsciences.com |
Investor Relations URL | https://investor.exactsciences.com/investor-relations/default.aspx |
HQ State/Province | Wisconsin |
Sector | Health Care |
Industry | Biotechnology |
Next Earnings Release | May. 01, 2025 |
Last Earnings Release | May. 01, 2025 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |